Date: 2016-09-15
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the ECTRIMS 2016
Company: Evgen Pharma (UK)
Product: SFX-01
Action
mechanism: neuroprotective agent. SFX-01 is a synthetic version of sulforaphane, a known neuroprotective and anti-cancer agent, which is stabilised in a novel patented complex using a proprietary manufacturing process. SFX-01 potentially represents a new class of drug in aneurysmal SAH with a mechanism of action that specifically targets the Nrf-2 pathway, which in turn reduces the oxidative stress and the toxicity caused by free hemoglobin from the haemorrhage.
Disease: multiple sclerosis
Therapeutic area: Neurodegenerative diseases
Country:
Trial details:
Latest
news: * On September 15, 2016, Evgen Pharma announced presentation of preclinical data of SFX-01 in various models of the relapsing remitting form of multiple sclerosis at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). The preclinical study focused on the comparison of SFX-01 with dimethyl fumarate, the active principle in BG-12, which is marketed as Tecfidera®. Results show that SFX-01 appears to exert maximum effects later in the course of the disease by enabling superior neurological recovery in the chronic stage after relapse. The poster is entitled Efficacy of SFX-01, a sulforaphane-based drug in experimental autoimmune encephalomyelitis". Evgen Pharma is conducting a commercial appraisal of the potential of SFX-01 in multiple sclerosis.
